Sebia is a specialized In Vitro Diagnostic player and the world’s leading provider of clinical protein electrophoresis equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy, and other rare pathologies.

Sebia

Our mission is to provide powerful tools that translate what is happening in a patients’ body into a readable and interpretable language.

We call it our new language of life. 

The “language of life” makes it easier to understand, diagnose and treat chronic and metabolic diseases produced by the modern way of life. Cancer, obesity, aging and depression share a common biology: they are metabolic and inflammatory. Those pathological imbalances lead to protein modification which require special separation techniques to give us a better understanding. Capillary Electrophoresis (CE) is the most accurate and efficient method of separation to unlock these complex conditions.

Sebia is a Global specialized In Vitro Diagnostic player and the world’s leading provider of clinical protein electrophoresis equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy and other rare pathologies.

Headquartered in the South of Paris (Lisses, France), We set high standards in making continuous advances in CE technology, scientific excellence and manufacturing capabilities, providing Sebia the possibility to pursue diagnostic solutions with an exciting pipeline of new tests and automated equipment.

Montagu

Astorg

HarbourVest Partners

Caisse de Depot et Placement du Quebec

🎄✨  Wishing you a Merry Christmas & Happy New Year from #Sebia 🎁 

#MerryChristmas #HappyNewYear #SeasonsGreetings

Mark your calendar to view our 2 Poster Presentations highlighting blood-based mass spectrometry for tracking #Myeloma in patients during #ASH.

📆Date: Sunday December 10th
🕕Time: 6:00 – 8:00 PM
📍Location: San Diego Convention Ctr, Halls G-H

#652: Multiple Myeloma: Clinical and Epidemiological
#654: MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological

#sebiausa #sebia #ash23 #multiplemyeloma #minsight #massspectrometry

Mark your calendar to visit the Sebia USA Team during ASH at booth 2455 to learn more about M-inSight, our new serum-based MRD test for monitoring Multiple #Myeloma!

#ASH23 #sebia #minsight #multiplemyeloma

The access to the educational webinar presented by Dr Ilaria Ferrarotti about improving the diagnosis of #AATD with the aid of Serum Protein Electrophoresis is still available.

➡️Take your seat here before it’s too late: https://lnkd.in/e49s7_f4

#A1AT #Alpha1Awareness #MakeYourMove #COPD #asthma

The access to the educational webinar presented by Pr Scarlata about the importance of #SPE and #A1AT phenotyping for a better patient management is still available.

➡️ Take your seat here before it’s too late: https://lnkd.in/eKJUbAHn

#Alpha1Awareness #MakeYourMove #AATD #COPD #asthma

Today is World #Diabetes Awareness Day.
Sebia is committed to support the International Diabetes Federation's initiatives to raise awareness on the access to diabetes care. 
Know your risk, Know your response.
 
#sebia #worlddiabetesday #hba1c #KnowYourRisk

You have a role to play in improving the diagnosis of Alpha-1 Antitrypsin Deficiencies. Diagnostic tools exist, they just need to be used!

Let's improve the time to diagnosis together!

➡️ Learn more about Sebia offer: https://lnkd.in/eTjtygGw

#A1AT #Alpha1Awareness #MakeYourMove #AATD #COPD #asthma

To learn more about Alpha-1 Antitrypsin and Sebia related offer, please visit this page: https://lnkd.in/efCp5GWm ⬅️

#A1AT #Alpha1Awareness #MakeYourMove #AATD #COPD #asthma

“We are proud to launch M-inSight® to improve the management of multiple #myeloma and quality of life for #patients, as well as assisting in the drug development and validation process. By testing in serum with equivalent sensitivity to bone marrow, we will solve current challenges in multiple myeloma #MRD-testing, allowing for a more frequent and reliable monitoring of response to treatment.”; Dr Pierre Sonigo, Chief Scientific Officer at Sebia.

#bonemarrow #minsight #multiplemyeloma

Did you know more than 3 million people worldwide suffer from Alpha-antitrypsin deficiency (#AATD) and the mean diagnositic delay was more than 5 years?
 
Join us for a live webinar on improving the diagnosis of AATD using serum protein electrophoresis with Dr. Ilaria Ferrarotti or register to access later the replay!

➡ Register to attend our live session and to watch the replay: https://lnkd.in/e7Jj9J7k

#COPD #alpha1antitrypsinedeficiency #geneticdisease #alpha1awareness #earlydiagnosis #wordlungday #lunghealth

COM:SEBIA

Sebia

locale

market

industry

website

crunchbase

linkedin

invested in

Metrics